MedTrace Logo

International Study of Inflammation in COVID-19

NCT04818866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4463

Last updated 2023-10-31

No results posted yet for this study

Summary

This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.

Conditions

Interventions

DIAGNOSTIC_TEST

SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase

Biomarkers of inflammation

Sponsors & Collaborators

  • Rush University

    collaborator OTHER

  • Copenhagen University Hospital, Hvidovre

    collaborator OTHER

  • University of Athens

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • University of Thessaly

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • University of Michigan

    lead OTHER

Principal Investigators

  • Salim S Hayek, MD · University of Michigan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818866 on ClinicalTrials.gov